Generic Name and Formulations:
Erythromycin 3%, benzoyl peroxide 5%; gel.
Cutanea Life Sciences, Inc.
Indications for AKTIPAK:
Contents must be mixed (in the palm of the hand) prior to use. Apply to cleansed, dried areas twice daily.
Avoid eyes, mouth, mucous membranes. Discontinue if excessive irritation occurs. Avoid excessive or prolonged exposure to sunlight. Flammable. Pregnancy (Cat.C). Nursing mothers.
Macrolide antibiotic + antibacterial/ keratolytic.
Additive irritation with peeling, desquamating, abrasive agents. Concomitant other topical acne products: not recommended.
Dry skin, application site reactions (eg, stinging, erythema, burning), blepharitis, pruritus, photosensitivity, peeling, superinfection; may bleach hair or fabrics.
Gel (dual-chamber pouches, mixed by patient)—60
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds